Blindness incidence in Germany - A population-based study from Württemberg-Hohenzollern

Few data on the incidence of blindness in Germany are available. We analysed causes of legal blindness for the region Württemberg-Hohenzollern (population 5.5 million) in order to help fill in this gap. Material and Methods: Population-based investigation on the incidence of legal blindness (visual acuity <1/50) based on materials from the social servies. Age-dependent blindness incidences were modelled via logistic regression models. Results: 647 blind persons were newly registered in 1994 (blindness incidence 11.6/100,000). The blindness incidence is moderate in infants (4.5/100,000) and decreases further during childhood. At the age of 20 years, the incidence again rises to the former level and remains relatively constant. After the age of 60 years, the incidence increases sharply: 5-year odds ratios are 1.76 (CI: 1.68-1.85) in women and 1.72 (CI: 1.60-1.84) in men. The blindness incidence is higher in women, 15.6/100,000, compared to 12.2/100,000 in men. The major causes of blindness are: macular degeneration, 3.92/100,000; diabetic retinopathy, 2.01/100,000; glaucoma, 1.6/100,000; high myopia, 0.77/100,000; optic atrophy, 0.68/100,000; central nervous system-triggered blindness; 0.56/100,000, and tapetoretinal degenerations, 0.52/100,000. Discussion: Due to monetary incentives for the blind persons, social service files offer accurate and complete data. Besides macular degeneration, glaucoma and dia betic retinopathy are major causes of blindness. Thus, this study suggests further blindness prevention activities for diabetic retinopathy and glaucoma

Automatic Diagnosis of Pathological Myopia from Heterogeneous Biomedical Data

10.1371/journal.pone.0065736PLoS ONE86

Cataract prevalence and prevention in Europe: a literature review

This literature review is aimed at the evaluation of the potential for cataract prevention in Europe. It was performed using Pub-MED with Mesh and free text terms. Studies included were: a) performed on a population of Caucasian origin at an age range of 40-95 years, b) cataract was clinically verified, c) drug record of prescriptions, their indication, a record of every diagnosis, dosage, and quantity of prescribed medicine were available, d) sample size >300, e) published between 1990 and 2009. The results of 29 articles were reviewed. Former (3.75 [2.26-6.21]) or current smoking (2.34 [1.07-5.15]), diabetes of duration >10 years (2.72 [1.72-4.28]), asthma or chronic bronchitis (2.04 [1.04-3.81]), and cardiovascular disease (1.96 [1.22-3.14]) increased the risk of cataract. Cataract was more common in patients taking chlorpromazine during >90 days with a dosage >300 mg, corticosteroids used >5 years (3.25 [1.39-7.58]) in a daily dose >1600 mg (1.69 [1.17-2.43]), a multivitamin/mineral formulation (2.00 [1.35-2.98]) or corticosteroids (2.12 [1.93-2.33]). Corticosteroid applied orally (3.25 [1.39-7.58]), parenteral (1.56 [1.34-1.82]) or inhalational (1.58 [1.46-1.71]) lead to cataract more frequently than those applied topically: nasal (1.33 [1.21-1.45]), ear (1.31 [1.19-1.45]), or skin (1.43 [1.36-1.50]). Outpatient cataract surgery was negatively associated with total cataract surgery costs, and chlorpromazine, corticosteroids, and multivitamin/mineral formation increase the risk of posterior sub-capsular cataract dependent on dose, treatment application, and duration. This review presented a comprehensive overview of specific and general cataract risk factors and an update on most recent experimental studies and randomized control trials directed at cataract prevention